Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20812027 | 0.86 | CRBN (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL20812170 | 0.85 | CRBN (0.47) | SMN1; SMN2MEN1KMT2ACRBNIKZF3 | |
| SCHEMBL27041904 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30796394 | 0.81 | TMEM97 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL31043982 | 0.80 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL31044005 | 0.80 | CRBN (0.51) | CRBNIKZF3DDB1 | |
| SCHEMBL30830567 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL27446193 | 0.79 | CRBN (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30938873 | 0.78 | CRBN (0.55) | CRBNIKZF3DDB1 | |
| SCHEMBL26929469 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | SMN1; SMN2 3654/4885NPC1 4262/4885RAB9A 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.